SubscribeAll Posts Tagged With: "gilead"
A Prescription for an Ailing Portfolio
In 1998 a 29-year old American received some of the worst news imaginable. He contracted the human immunodeficiency virus, HIV. It was a de facto death sentence.
Even the most optimistic person would have trouble looking on the bright side. Sure there were numerous advances in HIV treatment. People were living longer and longer with HIV. In 1998 it was common for people infected with HIV to live 10 years or more with the virus. And advances were being made consistently as billions of research dollars were going in to fighting HIV.
Had he contracted the virus a decade earlier in the 80’s,…
23Feb2009 | Q1 Publishing | 0 comments | ContinuedHealthcare In a State of Flux
Long thought to be an industry that could be banked on for stability by defensive investors during periods of turmoil, the healthcare industry should now be carefully navigated.
Two sectors within the industry that are worth noting right now are healthcare providers and biotech. These two sectors have experienced drastically different fates so far in 2008, and the trend might be expected to continue. Year-to-date, the iShares Dow Jones Healthcare Provider Fund (IHF) has choked on a loss of 46.4%. This performance is worse than that of the S&P 500 which is down 39.2% so far this year. It is far…
27Oct2008 | Oxbury Research | Comments Off | Continued
Loading ...
